Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System

Proteasome inhibitors (PIs) are an integral component of multiple myeloma therapies. Peripheral neuropathy (PN) is a well-known consequence of PIs, most frequently reported with earlier generations such as Bortezomib (BTZ). There is a paucity of data highlighting the risk of developing PN in the new...

詳細記述

書誌詳細

主要な著者:	Syeda A. Mina, Ibrahim Muhsen, Ethan Burns, Humaira Sarfraz, Sai Ravi Pingali, Jiaqiong Xu, Shahrukh K. Hashmi
フォーマット:	Artigo
言語:	Inglês
出版事項:	Turkish Society of Hematology 2021-08-01
シリーズ:	Turkish Journal of Hematology
主題:	multiple myeloma proteasome inhibitors peripheral neuropathy
オンライン･アクセス:	https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-28913
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!